Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Boris Freidlin

Showing results (111-120 of 118) with videos related to

Pageof 12
Sort By:
You have reached the last page of results.This site can display upto 118 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 2, 2008
Blinded independent central review of progression-free survival in phase III clinical trials: important design element or unnecessary expense?Lori E Dodd, Edward L Korn, Boris Freidlin, et al.
Cancer|September 19, 2002
Twenty-five years of clinical research for patients with limited-stage small cell lung carcinoma in North AmericaPasi A Jänne, Boris Freidlin, Scott Saxman, et al.
Clinical Trials (London, England)|January 16, 2025
Evaluating the impact of stratification on the power and cross-arm balance of randomized phase 2 clinical trialsAnna Moseley, Michael LeBlanc, Boris Freidlin, et al.
Clinical Trials (London, England)|August 13, 2013
An audit strategy for time-to-event outcomes measured with error: application to five randomized controlled trials in oncologyLori E Dodd, Edward L Korn, Boris Freidlin, et al.
Journal of the National Cancer Institute|December 13, 2012
NCI-RTOG translational program strategic guidelines for the early-stage development of radiosensitizersYaacov Richard Lawrence, Bhadrasain Vikram, James J Dignam, et al.
Blood Cancer Journal|June 29, 2022
Gaps and opportunities in the treatment of relapsed-refractory multiple myeloma: Consensus recommendations of the NCI Multiple Myeloma Steering CommitteeShaji Kumar, Lawrence Baizer, Natalie S Callander, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 18, 2007
Phase II clinical trial of chemotherapy-naive patients > or = 70 years of age treated with erlotinib for advanced non-small-cell lung cancerDavid M Jackman, Beow Y Yeap, Neal I Lindeman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 20, 2023
National Cancer Institute Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice (ComboMATCH)Funda Meric-Bernstam, James M Ford, Peter J O'Dwyer, et al.
Pageof 12

Showing results (111-120 of 118) with videos related to

Sort By:
Pageof 12
You have reached the last page of results.This site can display upto 118 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 2, 2008
Blinded independent central review of progression-free survival in phase III clinical trials: important design element or unnecessary expense?Lori E Dodd, Edward L Korn, Boris Freidlin, et al.
Cancer|September 19, 2002
Twenty-five years of clinical research for patients with limited-stage small cell lung carcinoma in North AmericaPasi A Jänne, Boris Freidlin, Scott Saxman, et al.
Clinical Trials (London, England)|January 16, 2025
Evaluating the impact of stratification on the power and cross-arm balance of randomized phase 2 clinical trialsAnna Moseley, Michael LeBlanc, Boris Freidlin, et al.
Clinical Trials (London, England)|August 13, 2013
An audit strategy for time-to-event outcomes measured with error: application to five randomized controlled trials in oncologyLori E Dodd, Edward L Korn, Boris Freidlin, et al.
Journal of the National Cancer Institute|December 13, 2012
NCI-RTOG translational program strategic guidelines for the early-stage development of radiosensitizersYaacov Richard Lawrence, Bhadrasain Vikram, James J Dignam, et al.
Blood Cancer Journal|June 29, 2022
Gaps and opportunities in the treatment of relapsed-refractory multiple myeloma: Consensus recommendations of the NCI Multiple Myeloma Steering CommitteeShaji Kumar, Lawrence Baizer, Natalie S Callander, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 18, 2007
Phase II clinical trial of chemotherapy-naive patients > or = 70 years of age treated with erlotinib for advanced non-small-cell lung cancerDavid M Jackman, Beow Y Yeap, Neal I Lindeman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 20, 2023
National Cancer Institute Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice (ComboMATCH)Funda Meric-Bernstam, James M Ford, Peter J O'Dwyer, et al.
Pageof 12